# BIOLOGICAL THERAPEUTICS PRODUCT DEVELOPMENT SUBJECT MATTER EXPERT CONSULTING SERVICES

> **NIH NIH N02** · — · 2024 · $79,500

## Abstract

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.
The NINDS has a need for biological therapeutics assay development subject matter expert
(SME) consultants to provide technical recommendations and advice that will support the
translational development of novel therapeutics (Biologics) for NIH drug discovery and
development programs. The support included in this contract will cover bioassay development
and/or qualification/validation for a variety of biologics including but not limited to: monoclonal
antibodies, peptide therapeutics, viral vector therapeutics (e.g., AAV, lentiviruses, etc.), nucleic
acid and cell-based therapeutics, proteins, or other biological therapeutic modalities. Preferably,
consultants should have significant expertise supporting assay development for more than one
biological therapeutic modality (e.g., monoclonals, peptides, ASOs and viral vectors).

## Key facts

- **NIH application ID:** 11211343
- **Project number:** 75N95024P00020-P00001-0-2
- **Recipient organization:** —
- **Principal Investigator:** —
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $79,500
- **Award type:** —
- **Project period:** 2023-11-17 → 2024-11-16

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11211343

## Citation

> US National Institutes of Health, RePORTER application 11211343, BIOLOGICAL THERAPEUTICS PRODUCT DEVELOPMENT SUBJECT MATTER EXPERT CONSULTING SERVICES (75N95024P00020-P00001-0-2). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11211343. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*